Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Insmed Incorporated
INSM | US
135.17
USD-8.66
-6.02%
INSM | US
Loading StockChartView...
About Insmed Incorporated
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
24/04/2026
Close
135.17
Open
142.29
High
143.27
Low
134.59
Insmed Incorporated a biopharmaceutical company develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis cystic fibrosis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater New Jersey.
View LessINSM | US
Risk
51.1
Sharpe
1.65
Luna's Score
48/100
Recommendation
Hold
Luna says (INSM | US)
What's Working
Largecap (10B - 200B USD)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
40.9%1 month
51.1%3 months
45.4%6 months
51.0%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
329.99
Debt to equity
35.53
Debt to assets
0.76
Ent. to EBITDA
-6.05
Ent. to rev.
38.89
PEG
-
Other Fundamentals
EBITDA
-634.95M
MarketCap
23.23B
MarketCap(USD)
23.23B
Div. yield
-
Op. margin
-205.01
Erngs. growth
-
Rev. growth
17.00
Ret. on equity
-1.45K
Short ratio
7.06
Short perc.
7.79
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
25.41
Range1M
31.60
Range3M
32.78
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.14
Price X volume
336.97M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -6.05 | 0.53 | Cheaper |
| Ent. to Revenue | 38.89 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 329.99 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 45.37 | 72.80 | Lower Risk |
| Debt to Equity | 35.53 | -1.23 | Expensive |
| Debt to Assets | 0.76 | 0.25 | Expensive |
| Market Cap | 23.23B | 3.66B | Market Leader |
